A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Go Back to All Clinical Trials

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Brief description of study

Clinical Study Identifier: s23-00634

ClinicalTrials.gov Identifier: NCT05945823

Principal Investigator: Jennifer Chuy.

Other Investigators: Laura Palazzolo, Daniel J Becker, Marta Wioleta Wronska, Kristen Spencer, Jonathan B Kahn, Keriann M Scavone, Nitish Mehta, Nina Beri, Paul E. Oberstein, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies